Screener
Supernus Pharmaceuticals SUPN Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Amortization of premium/discount on marketable securities | (192) | (1,074) |
| Change in fair value of contingent consideration | 2,391 | 7,660 |
| Realized loss (gain) from sale of marketable securities | (21) | 9 |
| Share-based compensation expense | 8,480 | 8,068 |
| Deferred income tax expense (benefit) | 5,916 | (3,990) |
| Noncash lease expense | 2,258 | 1,341 |
| Inventory valuation write-down | 1,815 | 547 |
| Payment of contingent consideration | — | (4,900) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's stock-based comp?
- Supernus Pharmaceuticals (SUPN) reported stock-based comp of $8.48M in Q1 2026.
- How has Supernus Pharmaceuticals's stock-based comp changed year-over-year?
- Supernus Pharmaceuticals's stock-based comp increased by 5.1% year-over-year, from $8.07M to $8.48M.
- What is the long-term trend for Supernus Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's stock-based comp has grown at a 16.6% compound annual growth rate (CAGR), from $17.91M to $33.05M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Supernus Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude